- Conditions
- Endothelial Dysfunction, Gestational Diabetes, Physical Inactivity
- Interventions
- Insulin aspart
- Drug
- Lead sponsor
- Anna Stanhewicz, PhD
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2665–2688
of 22,020
matching trials from the local directory fallback.
- Conditions
- Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
- Interventions
- Methotrexate Infusion, Methotrexate Injection, Sham Injection
- Drug
- Lead sponsor
- Cincinnati Eye Institute, Southwest Ohio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Cardiovascular Diseases, Heart Valve Diseases, Tricuspid Valve Regurgitation
- Interventions
- Transcatheter Tricuspid Valve Replacement
- Device
- Lead sponsor
- TRiCares
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 5 more
- Conditions
- Bladder Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Mesothelioma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Pheochromocytoma/Paraganglioma (PPGL), Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
- Interventions
- [18F]FAPI-74, [18F]FDG
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Electronic Cigarette Use, Endothelial Dysfunction, Inflammation
- Interventions
- Placebo, Salsalate 750 MG Oral Tablet [DISALCID]
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Hybrid Closed Loop Insulin Pump System
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Sylmar, California • Torrance, California
- Conditions
- Multiple Sclerosis
- Interventions
- No intervention
- Other
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years to 50 Years · Female only
- Enrollment
- 728 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Biliary Tract Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- Cisplatin, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Pembrolizumab, Rescue medication, Sacituzumab tirumotecan, Supportive care measures
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
- Conditions
- NSCLC, Non-small Cell Lung Cancer
- Interventions
- Carboplatin, Nab-paclitaxel, Paclitaxel, Pembrolizumab, sac-TMT
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 851 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • Burbank, California • San Diego, California + 17 more
- Conditions
- Pain, Chronic
- Interventions
- Experimental: Group #1: Virtual Reality Headset, Group 2 No Virtual Reality Headset
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Higher Risk Myelodysplastic Syndromes, Myelodysplastic Syndromes
- Interventions
- REM-422
- Drug
- Lead sponsor
- Remix Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Duarte, California • Tampa, Florida • Boston, Massachusetts + 2 more
- Conditions
- Alzheimer Disease
- Interventions
- Flortaucipir F18, LY3954068, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Maitland, Florida • The Villages, Florida • Decatur, Georgia + 3 more
- Conditions
- Malignant Solid Neoplasm
- Interventions
- Best Practice, Financial Navigation, Interview, Survey Administration
- Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- Not listed
- Enrollment
- 760 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 383
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 252 more
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Echocardiography Test, Iadademstat, Magnetic Resonance Imaging, Multigated Acquisition Scan
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 43
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 37 more
- Conditions
- Candida Auris Infection, Colonization, Asymptomatic
- Interventions
- Povidone Iodine Topical
- Drug
- Lead sponsor
- Mary K Hayden
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Hinsdale, Illinois
- Conditions
- Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
- Interventions
- ATG dosing platform when combined with standard tacrolimus and mini methotrexate
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic
- Interventions
- Exercise Intervention
- Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- ALL, AML, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, B Cell Lymphoma, Burkitt Lymphoma, CML, Chronic Myelogenous Leukemia, Cutaneous B-Cell Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Hematologic Malignancy, Hodgkin Lymphoma, Leukemia, Lymphoma, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma, T-cell Lymphoma
- Interventions
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 0 Years to 38 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Cincinnati, Ohio + 3 more
- Conditions
- Wounds and Injuries
- Interventions
- APPRAISE Trauma Clinical Decision Support System
- Device
- Lead sponsor
- Andrew Tomas Reisner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Myotonic Dystrophy Type 1
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Brain Metastases, Breast Cancer
- Interventions
- Brain Imaging with 18F-FES
- Diagnostic Test
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
- Interventions
- 18F-fluciclovine, PET/CT
- Drug · Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
- Interventions
- UPLIZNA
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 15 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Deafness
- Interventions
- Electrode-Neural Interface
- Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 2 Years to 90 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York